Akebia Therapeutics Inc
Veridion Score
BETAHIGH CONF · 6/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is AKBA moving today?
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
AKBA overview
Related filings and maps
Congress activity in AKBA
No receipt-qualified Congressional disclosure is present for AKBA in the cached public ledger.
AKBA contract awards, year to date.
Public federal awards linked to this ticker.
AKBA lobbying filings, year to date.
Registered lobbying filings matched to Akebia Therapeutics Inc.
AKEBIA THERAPEUTICS, INC.
AKEBIA THERAPEUTICS, INC.
AKEBIA THERAPEUTICS, INC.